, and/or arousal disorders, with SSEs relegated to a 407 secondary endpoint:8 The FDA also considers this approach acceptable. 408 409 2. Other Secondary Endpoints 410 411 Definitions of a responder demonstrating improvement in SSEs, interest, desire, arousal, or 412 distress also can be assessed as seconda